Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
12/09/2025
Microsoft and OpenAI announced on Thursday that they have signed a non-binding agreement on new terms for their relationship. This agreement will allow OpenAI to advance its restructuring plan to become a for-profit company.
Latest
1 m ago
The Nikkei futures index rose 0.88% in early trading in Japan.
2 m ago
Turning point is approaching, new forces in car manufacturing are making a profit sprint.
3 m ago
Securities Times: Expectations for the central bank to restart government bond trading operations are rising, with the timing potentially in the fourth quarter.
3 m ago
Ka Li Pharmaceutical: Controlling shareholders make a voluntary commitment to a sales ban.
3 m ago
Galecto Biotech announced on the Hong Kong Stock Exchange that the Board of Directors hereby announces that Dr. Hans Schambye (founder of Galecto, Chairman and CEO of the Board, and major shareholder of the Company) and Ms. Hoi Ching To (Executive Director and major shareholder of the Company, spouse of Dr. Schambye) have voluntarily committed not to sell (including but not limited to selling or pledging) any shares of the Company held by them or controlled by them directly or indirectly, until the release of the following three clinical data, in order to express their firm confidence in the Company's long-term value and future prospects.
See all latest